XML 53 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue (Tables)
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table summarizes our revenue recognized in our consolidated statements of operations:
202420232022
Net product revenue$40,747.9 $28,813.9 $25,462.8 
Collaboration and other revenue4,294.8 5,310.2 3,078.6 
Revenue$45,042.7 $34,124.1 $28,541.4 
The following table summarizes revenue, including net product revenue and collaboration and other revenue, by product:
U.S.Outside U.S.
202420232022202420232022
Cardiometabolic Health:
Mounjaro$8,949.9 $4,834.2 $366.6 $2,590.2 $328.9 $115.9 
Trulicity3,693.8 5,433.3 5,688.8 1,559.7 1,699.2 1,750.9 
Zepbound4,925.7 175.8 — — — — 
Jardiance(1)
1,597.5 1,600.4 1,194.5 1,743.4 1,144.2 871.5 
Humalog(2)
1,502.6 863.2 1,191.9 822.2 800.2 868.7 
Humulin643.4 610.1 730.2 273.7 242.0 289.2 
Basaglar(3)
375.4 443.1 470.7 301.5 285.2 289.7 
Baqsimi
2.5 645.7 110.4 26.7 31.9 28.9 
Other cardiometabolic health159.6 175.0 158.0 353.1 355.2 338.9 
Total cardiometabolic health21,850.4 14,780.8 9,911.1 7,670.5 4,886.8 4,553.7 
Oncology:
Verzenio3,420.6 2,509.0 1,653.2 1,886.0 1,354.3 830.3 
Cyramza442.2 402.3 351.4 531.0 572.4 620.0 
Erbitux562.1 528.9 500.1 65.3 67.6 66.4 
Tyvyt— — — 526.0 393.4 293.3 
Other oncology610.9 356.8 713.4 708.3 473.6 638.1 
Total oncology5,035.8 3,797.0 3,218.1 3,716.6 2,861.3 2,448.1 
Immunology:
Taltz2,152.3 1,831.6 1,724.6 1,108.1 928.0 757.4 
Olumiant(4)
228.7 225.5 148.2 728.7 697.2 682.3 
Other immunology76.6 0.8 20.0 98.5 114.4 12.1 
Total immunology2,457.6 2,057.9 1,892.8 1,935.3 1,739.6 1,451.8 
Neuroscience:
Emgality559.7 482.2 462.8 310.7 196.0 188.1 
Zyprexa(5)
2.0 79.4 30.4 114.3 1,615.4 306.5 
Other neuroscience218.2 134.4 119.2 268.5 371.1 439.2 
Total neuroscience779.9 696.0 612.4 693.5 2,182.5 933.8 
Other:
COVID-19 antibodies(6)
— — 2,008.9 — — 14.7 
Other251.4 459.3 546.8 651.6 662.9 949.3 
Total other251.4 459.3 2,555.7 651.6 662.9 964.0 
Revenue$30,375.2 $21,791.0 $18,190.0 $14,667.5 $12,333.1 $10,351.3 
Numbers may not add due to rounding.
(1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR.
(2) Humalog revenue includes insulin lispro.
(3) Basaglar revenue includes Rezvoglar.
(4) Olumiant revenue includes sales for baricitinib that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.
(5) Zyprexa revenue includes sale of rights for the olanzapine portfolio in July 2023.
(6) COVID-19 antibodies include sales for bamlanivimab administered alone, for bamlanivimab and etesevimab administered together, and for bebtelovimab and were made pursuant to EUAs or similar regulatory authorizations.
The following table summarizes revenue by geographical area:
202420232022
Revenue(1):
U.S.$30,375.2 $21,791.0 $18,190.0 
Europe6,920.7 6,174.7 4,299.2 
Japan1,814.9 1,672.6 1,747.3 
China1,660.4 1,539.7 1,452.8 
Rest of world4,271.4 2,946.2 2,852.0 
Revenue$45,042.7 $34,124.1 $28,541.4 
Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer or other party
Schedule of Amounts Recorded for Contract Liabilities
The following table summarizes contract liability balances at December 31:
 20242023
Contract liabilities$166.3 $193.6